$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE

PR Newswire

NEW YORK, July 3, 2025

NEW YORK , July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the  Empire State Building  in New York City and are investigating

• Carisma Therapeutics Inc. (NASDAQ: CARM)  related to its sale to OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company.

Click here for more information https://monteverdelaw.com/case/carisma-therapeutics-inc/ . It is free and there is no cost or obligation to you.

• Guaranty Bancshares, Inc. (NYSE:GNTY)  related to its sale to Glacier Bancorp, Inc. Upon completion of the proposed transaction, existing Guaranty shareholders will receive 1.0000 share of Glacier common stock for each share of Guaranty (subject to certain adjustments).

Click here for moreinformation https://monteverdelaw.com/case/guaranty-bancshares-inc/.It is free and there is no cost or obligation to you.

• Turnstone Biologics Corp. (NASDAQ: TSBX)  related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right.

Click here for moreinformation https://monteverdelaw.com/case/turnstone-biologics-corp/.It is free and there is no cost or obligation to you.

• Sage Therapeutics, Inc. (NASDAQ: SAGE)  related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026 ; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028 ; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030 .

Click here for more information https://monteverdelaw.com/case/sage-therapeutics-inc/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

1. Do you file class actions and go to Court?
2. When was the last time you recovered money for shareholders?
3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law.  If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website  or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com  or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( www.monteverdelaw.com ). Prior results do not guarantee a similar outcome with respect to any future matter.

View original content to download multimedia: https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-investigates-the-merger-carm-gnty-tsbx-and-sage-302497917.html

SOURCE Monteverde & Associates PC

Läs mer på PR Newswire